Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa

Abstract

Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm of hematopoietic stem cells characterized by excessive accumulation of myeloid cells. Previously the treatment of the disease was based only on chemotherapy and allogeneic transplantation. Today the treatment is based on the 1st, 2nd and 3rd generation tyrosine kinase inhibitors Material and Methods: A narrative review was performed in the Lilacs, Scielo and Pubmed databases using the terms: ("CML") ("tyrosine kinase inhibitors ") And (" treatment "). Results: Of the articles found in more than one database, 18 articles were analyzed and read in their entirety. Of which 8 were carried out in Brazil, 6 in the United States and only one in Germany, Italy, Japan and Taiwan respectively, publications are in the period from 2009 to 2015. 44.44% (8) are articles of revision and 55.56% (10) were original articles. Review articles were excluded from this research. Regarding the drugs studied, 50% (5) had as study focus the drug Imatinib; 30% (3) compared the drugs Imatinib, Dasatinib and Nilotinib in relation to the therapeutic response; 10% (1) also evaluated the therapeutic response of Imatinib, Busutinib and Ponatinib; and 10% (1) of the studies evaluated only Dasatinib. Conclusion: Second- and third-generation tyrosine kinase inhibitors, when compared in the literature to the first generation drug (Imatinib), present a faster therapeutic response, greater survival and a better quality of life.